Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23019043 | 0.88 | ENPP2 (0.45) | LMNAERCC1ERCC4NOTUMKAT6A | |
| SCHEMBL5934873 | 0.81 | NOTUM (0.57) | LMNAERCC1ERCC4NOTUMKAT6A | |
| SCHEMBL540011 | 0.80 | NOTUM (0.58) | LMNANOTUMKDM4EALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL6006151 | 0.79 | NOTUM (0.55) | LMNAERCC1ERCC4NOTUMKAT6A | |
| SCHEMBL29134867 | 0.78 | KEAP1 (0.63) | NOTUMKDM4EALDH1A1ENPP2MGLL | |
| SCHEMBL30016360 | 0.78 | KEAP1 (0.63) | NOTUMKDM4EALDH1A1ENPP2MGLL | |
| SCHEMBL31057726 | 0.78 | KDM4E (0.44) | LMNAERCC1ERCC4NOTUMKAT6A | |
| Hydrochloric Acid SCHEMBL30710779 | 0.77 | KDM4E (0.43) | LMNAERCC1ERCC4NOTUMKAT6A | |
| SCHEMBL27785304 | 0.77 | LMNA (0.45) | LMNAERCC1ERCC4NOTUMKAT6A | |
| SCHEMBL16115191 | 0.77 | KAT6A (0.41) | LMNANOTUMKAT6AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | Bial—R&D Investments, S.A. (PT) | 2024-10-15 | — | — | US | disclosed |
| EP-3313828-B1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023107603-A1 | PYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4069678-A1 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115052862-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-109311887-B | Pyrazolo [1,5-a ] pyrimidinecarboxamide compounds and their use in the treatment of medical conditions | BIAL研发投资股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-12-07 | — | — | US | disclosed |
| US-7144913-B2 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2006-12-05 | — | — | US | disclosed |
| EP-1395590-B1 | DIHYDROPYRROLO¬1,2-A|INDOLE AND TETRAHYDROPYRIDO¬1,2-A|INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA INC (CA) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006058648-A2 | BIARYLOXYMETHYLARENE CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| EP-1395590-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-A]INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094830-A2 | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116369-B2 | Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators | GBA1, GALC, GBA3 | LMNA 2924/4885ERCC1 4157/4885ERCC4 3724/4885 |
| US-11192892-B2 | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders | GBA1, PARK7, GAA | LMNA 2615/4885ERCC1 3669/4885ERCC4 3638/4885 |
| US-20230098494-A1 | PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, PARK7 | LMNA 1317/4885ERCC1 3314/4885ERCC4 3610/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | LMNA 422/4885ERCC1 4066/4885ERCC4 2970/4885 |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | LMNA 4685/4885ERCC1 4716/4885ERCC4 4795/4885 |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | LMNA 4537/4885ERCC1 2119/4885ERCC4 3482/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | LMNA 3425/4885ERCC1 1838/4885ERCC4 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.